<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257061</url>
  </required_header>
  <id_info>
    <org_study_id>DECEMS1010</org_study_id>
    <nct_id>NCT01257061</nct_id>
  </id_info>
  <brief_title>Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment</brief_title>
  <official_title>Unicentric Comparing Effectiveness Superiority of to Clemastine Fumarate 1, 0 mg/g + Dexamethasone 0, 5 mg/g to Dexchlorpheniramine Maleate 10 mg/g in Eczema Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and
      impaired quality of life due specially pruritus and physical visible skin lesions. The
      propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g +
      dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      • Double blinded, superiority, prospective parallel-group, intend to treat trial.

      Study design:

        -  Experiment duration: 22 days

        -  2 visits (days 1,7,15 and 22)

        -  Reducing Eczema Area and severity index evaluation

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2012</start_date>
  <completion_date type="Actual">August 2, 2013</completion_date>
  <primary_completion_date type="Actual">April 30, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction / improvement of signs and symptoms</measure>
    <time_frame>DAY 22</time_frame>
    <description>The reduction of signs an symptoms will be evaluated by OSAAD index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Evaluation</measure>
    <time_frame>DAY 22</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexchlorpheniramine maleate 10 mg/g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1</intervention_name>
    <description>Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2</intervention_name>
    <description>Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with acute or sub-acute eczema.

          3. Presence of symmetric lesions to compare on side to the other.

        Exclusion Criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation

          3. Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study).

          4. Sunlight over exposure in the last 15 days.

          5. Any pathology or past medical condition that can interfere with this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavia Addor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medcin Instituto da Pele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medcin instituto da Pele</name>
      <address>
        <city>Osasco</city>
        <state>São Paulo</state>
        <zip>060323-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermatitis</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

